Live tape
Top 8, mentions 7d7,637NVDA1,345 mentions▲ +0.09GOOGL1,166 mentions▲ +0.04AVGO1,034 mentions▲ +0.05NKE1,030 mentions+0.01LULU964 mentions▲ +0.03TSLA923 mentions▲ +0.06META634 mentions▲ +0.05QQQ541 mentions▲ +0.08

Equity · Healthcare

RGEN

Repligen Corporation · NasdaqGS

$141 −2.08% 1D Finazon · prior-day close · Jul 31, 2026
Price · Chart
Our own end-of-day closes 36 sessions
$150 $120 10 Jun 31 Jul

The line runs $131 on 10 June through $141 on 31 July, on a scale from $120 to $150. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of RGEN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 36 sessions over that window: $131 on 10 June 2026 through $141 on 31 July 2026.

Market cap $8.0B
P/E (TTM) 185.5
52-week range $102.85 – $172
Avg volume 410.3K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

RGEN insider trades

SEC Form 4 · last 90 days · newest reported trade 20 Aug 2026
Open-market buys 0
Open-market sells 1
Net sold $977K
Non-trade filings 2
Date Insider Type Shares Value
20 Aug 2026 Loeillot Olivier Chief Executive Officer Sell 5,426 $977K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Sep 2026 Hughes Violetta CHIEF ACCOUNTING OFFICER Tax withheld 277 $47K
20 Aug 2026 Loeillot Olivier Chief Executive Officer Option exercise 5,426 $769K

RGEN reported financials

SEC EDGAR XBRL

RGEN reported revenue of $738.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was $48.9M.

Figure Reported Period
Revenue $738.3M 31 Dec 2025 fiscal year
Net income $48.9M 31 Dec 2025 fiscal year
Diluted EPS $0.86 31 Dec 2025 fiscal year
Total assets $3.0B 30 Jun 2026 at period end
Total equity $2.1B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

RGEN earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.09 —
31 Mar 2026 Q1 2026 $0.15 —
31 Dec 2025 FY 2025 $0.86 —
30 Sep 2025 Q3 2025 $0.26 —
30 Jun 2025 Q2 2025 $0.26 —
31 Mar 2025 Q1 2025 $0.10 —
31 Dec 2024 FY 2024 $-0.46 —
30 Sep 2024 Q3 2024 $-0.01 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

RGEN institutional holders

SEC Form 13F

11 of the 45 institutional funds we track reported a RGEN position for the quarter ended 30 Jun 2026 — a combined $462.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Maverick Capital Added +30.7% shares 1,984,554 $270.8M
Citadel Advisors Trimmed −65.8% shares 376,309 $51.3M
Balyasny Asset Management Added +183.3% shares 355,507 $48.5M
Marshall Wace New position 282,107 $38.5M
Point72 Asset Management Trimmed −70.8% shares 166,157 $22.7M
D. E. Shaw & Co. New position 83,328 $11.4M
Duquesne Family Office New position 77,400 $10.6M
Tudor Investment Corp New position 25,678 $3.5M
Man Group Added +81.9% shares 20,341 $2.8M
Two Sigma Investments New position 9,901 $1.4M

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

RGEN fails-to-deliver

SEC CNS data

On 13 Aug 2026, 52 shares of RGEN failed to deliver (about $9K).

Settlement date Shares failed Notional % of shares out
13 Aug 2026 52 $9K <0.001%
10 Aug 2026 15 $2K <0.001%
07 Aug 2026 234 $37K <0.001%
04 Aug 2026 6,257 $920K 0.011%
03 Aug 2026 1,376 $194K 0.002%
30 Jul 2026 29 $4K <0.001%
28 Jul 2026 6,541 $857K 0.012%

Source: SEC fails-to-deliver (CNS) data